Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma | Zendy

Kira Bona | Zendy; Yimei Li | Zendy; Lena E. Winestone | Zendy; Kelly Getz | Zendy; YuanShung Huang | Zendy; Brian T. Fisher | Zendy; Ami V. Desai | Zendy; Troy Richardson | Zendy; Matt Hall | Zendy; Arlene Naranjo | Zendy; Tara O. Henderson | Zendy; Richard Aplenc | Zendy; Rochelle Bagatell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma

Author(s) -

Kira Bona,

Yimei Li,

Lena E. Winestone,

Kelly Getz,

YuanShung Huang,

Brian T. Fisher,

Ami V. Desai,

Troy Richardson,

Matt Hall,

Arlene Naranjo,

Tara O. Henderson,

Richard Aplenc,

Rochelle Bagatell

Publication year - 2020

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djaa107

Subject(s) - neuroblastoma , poverty , oncology , medicine , immunotherapy , clinical trial , child survival , pediatric oncology , cancer , biology , economic growth , survivorship curve , economics , genetics , cell culture

Whether social determinants of health are associated with survival in the context of pediatric oncology-targeted immunotherapy trials is not known. We examined the association between poverty and event-free survival (EFS) and overall survival (OS) for children with high-risk neuroblastoma treated in targeted immunotherapy trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research